Journal of clinical and experimental hematopathology : JCEH最新文献_第7页

Brentuximab vedotin monotherapy for CD30-positive adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells. Brentuximab vedotin单药治疗htlv -1感染霍奇金细胞和里德-斯特伯格样细胞的cd30阳性成人t细胞白血病/淋巴瘤

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25019

Shun Ito, Hiromichi Takahashi, Haruna Watanabe-Nishimaki, Kennosuke Karube, Takahiro Namiki, Takashi Hamada, Shimon Otake, Katsuhiro Miura, Hideki Nakamura

{"title":"Brentuximab vedotin monotherapy for CD30-positive adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells.","authors":"Shun Ito, Hiromichi Takahashi, Haruna Watanabe-Nishimaki, Kennosuke Karube, Takahiro Namiki, Takashi Hamada, Shimon Otake, Katsuhiro Miura, Hideki Nakamura","doi":"10.3960/jslrt.25019","DOIUrl":"10.3960/jslrt.25019","url":null,"abstract":"Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy associated with human T-lymphotropic virus 1 (HTLV-1) infection. In this case study, we present a male patient diagnosed with CD30-positive ATLL, a rare pathological subtype characterized by the presence of HTLV-1-infected Hodgkin and Reed-Sternberg-like (HRS-like) cells. The patient was considered unsuitable for intensive chemotherapy due to advanced age and severe comorbidities. Consequently, the patient was treated with brentuximab vedotin (BV) monotherapy. Following five cycles of BV, the patient achieved partial remission (PR) without significant adverse events. Eight months have passed since the end of treatment, and the disease has not progressed. The positive results of this study suggest that BV monotherapy could be considered a viable treatment option for older or frail patients with CD30-positive ATL, particularly those with HTLV-1-infected HRS-like cells, who may not be able to tolerate standard multi-agent chemotherapy.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"65 2","pages":"140-145"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma. 1例淋巴瘤患者嵌合抗原受体t细胞治疗后裂叶菌感染。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25043

Risa Nishiyama, Shinichi Makita, Mika Shiotsuka, Osamu Kobayashi, Akira Watanabe, Akiko Miyagi Maeshima, Tetsuro Ochi, Noriko Iwaki, Suguru Fukuhara, Wataru Munakata, Koji Izutsu

{"title":"Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma.","authors":"Risa Nishiyama, Shinichi Makita, Mika Shiotsuka, Osamu Kobayashi, Akira Watanabe, Akiko Miyagi Maeshima, Tetsuro Ochi, Noriko Iwaki, Suguru Fukuhara, Wataru Munakata, Koji Izutsu","doi":"10.3960/jslrt.25043","DOIUrl":"10.3960/jslrt.25043","url":null,"abstract":"Infectious complications are common following chimeric antigen receptor (CAR) T-cell therapy for B-cell lymphoma due to its prolonged immunosuppressive effects. Schizophyllum commune is an exceedingly rare fungal pathogen that typically affects the respiratory tract and may mimic chronic pulmonary aspergillosis. Infections caused by S. commune have been primarily reported in recipients of allogeneic hematopoietic stem cell transplantation. Here, we report the first known case of S. commune infection in a patient treated with CAR T-cell therapy. A 71-year-old woman with primary refractory large B-cell lymphoma received lisocabtagene maraleucel as second-line therapy. Six months post-treatment, computed tomography revealed right middle lobe atelectasis with high-attenuation mucus. Bronchoscopic biopsy, fungal culture, and internal transcribed spacer gene region sequencing confirmed the diagnosis of S. commune infection presenting as allergic bronchopulmonary mycosis (ABPM). Notably, serologic tests were negative for fungus-specific specific immunoglobulin G and immunoglobulin E. The patient responded favorably to 4 months of oral voriconazole therapy, with resolution of symptoms and radiologic findings. This case highlights the potential for rare fungal infections, such as S. commune, to occur following CAR T-cell therapy. Although the clinical and radiologic features were consistent with ABPM, the absence of serologic markers underscores the diagnostic challenges posed by B-cell aplasia resulting from B-cell-directed immunotherapy.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"65 3","pages":"210-217"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12598707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145188282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chimeric antigen receptor T-cell and bispecific antibody therapies for follicular lymphoma: Recent advances and future prospects. 嵌合抗原受体t细胞和双特异性抗体治疗滤泡性淋巴瘤：最新进展和未来展望。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25050

Tsutomu Kobayashi

{"title":"Chimeric antigen receptor T-cell and bispecific antibody therapies for follicular lymphoma: Recent advances and future prospects.","authors":"Tsutomu Kobayashi","doi":"10.3960/jslrt.25050","DOIUrl":"10.3960/jslrt.25050","url":null,"abstract":"Patients with follicular lymphoma are expected to have relatively long survival due to slow disease progression, but the disease generally relapses repeatedly and remains incurable. Therefore, development of treatments for relapsed or refractory follicular lymphoma is an urgent issue. The recent introduction of cellular immunotherapy has significantly changed treatment of B-cell malignancies. Clinical development of anti-CD19 chimeric antigen receptor (CAR)-T cell therapy and CD20×CD3 bispecific antibody therapy for follicular lymphoma is underway. Multiple studies have also reported the effectiveness of CAR-T cell and bispecific antibody therapies for relapsed or refractory follicular lymphoma, and some cellular immunotherapies have already been approved in Japan. While CAR-T therapy is highly effective and may offer a functional cure in some patients, it faces challenges such as limited access, high cost, and high toxicities. Bispecific antibodies, in contrast, have relatively mild toxicities and can be widely used in patients with poor general conditions, including elderly patients, but have problems such as the burden of long-term administration. Optimal patient selection, management of unique toxicities, and high costs remain issues to be resolved for cellular immunotherapy. This review summarizes the recent clinical data on cellular immunotherapy for follicular lymphoma.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"65 4","pages":"253-258"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12883024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145829740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A therapeutic effect of Forodesine for CNS relapsed primary testicular T cell lymphoma after allogeneic transplantation. 福罗地辛治疗中枢神经系统原发性睾丸T细胞淋巴瘤异体移植后复发的疗效观察。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25032

Hiroki Tsutsumi, Masahisa Kudo, Nobuo Maseki, Yasunobu Sekiguchi, Hirofumi Kobayashi

引用次数: 0

Monotypic versus monoclonal: Conceptual distinction in B-cell lymphoproliferative disorders. 单型与单克隆：b细胞淋巴增生性疾病的概念区别。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25025

Hirokazu Nakamine

引用次数: 0

Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma. 弥漫性大b细胞淋巴瘤中CD20/CD3双特异性抗体的发展和生物标志物

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25055

Chisako Iriyama

引用次数: 0

Bruton tyrosine kinase inhibitor in non-IgM lymphoplasmacytic lymphoma: a case report and literature review. 布鲁顿酪氨酸激酶抑制剂治疗非igm淋巴浆细胞性淋巴瘤1例报告并文献复习。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25040

Kenichi Ito, Kazuhiko Hirano, Naohiro Sekiguchi

引用次数: 0

Prognostic and immunomodulatory roles of CD30 in diffuse large B-cell lymphoma: a cell-of-origin- and microenvironment-dependent paradigm. CD30在弥漫性大b细胞淋巴瘤中的预后和免疫调节作用：细胞起源和微环境依赖范式

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25048

Yuka Tanaka

{"title":"Prognostic and immunomodulatory roles of CD30 in diffuse large B-cell lymphoma: a cell-of-origin- and microenvironment-dependent paradigm.","authors":"Yuka Tanaka","doi":"10.3960/jslrt.25048","DOIUrl":"10.3960/jslrt.25048","url":null,"abstract":"The expression of CD30 in diffuse large B-cell lymphoma (DLBCL) has long been debated regarding its clinical significance. This report synthesizes the conflicting findings on CD30 and proposes a new paradigm. Central to this concept is that the prognostic value and biological function of CD30 are critically dependent on the lymphoma cell-of-origin (COO) and tumor microenvironment (TME) it shapes. Analysis of large-scale public gene expression datasets revealed that high CD30 expression is an independent favorable prognostic factor in DLBCL, but this effect is exclusively confined to the germinal center B-cell-like subtype. In contrast, CD30 expression showed no prognostic significance in the activated B-cell-like subtype. This specificity is attributable to CD30's role as a key architect of the TME, inducing an immune-tolerant environment, particularly through CD4+ T-cell infiltration and recruitment of regulatory T-cells. This understanding provides a strong rationale for COO- and TME-guided therapeutic strategies, such as combining the anti-CD30 antibody-drug conjugate brentuximab vedotin with immunomodulatory agents. This report elucidates the enigma of CD30 and outlines a path towards personalized medicine for DLBCL.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"65 4","pages":"247-252"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12884142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145829777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma. 外周t细胞淋巴瘤对普拉曲酯长期有效的病例系列。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25013

Naoto Tomita, Koichi Kitazume, Toshiki Kitajima, Hiroki Hayata, Shuku Sato, Naoya Nakamura

{"title":"Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma.","authors":"Naoto Tomita, Koichi Kitazume, Toshiki Kitajima, Hiroki Hayata, Shuku Sato, Naoya Nakamura","doi":"10.3960/jslrt.25013","DOIUrl":"10.3960/jslrt.25013","url":null,"abstract":"Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of diseases with a tendency to relapse and poor prognosis, especially in relapsed or refractory cases. The prognosis of patients who are not eligible for autologous hematopoietic stem cell transplantation, such as older adults and those who do not respond to chemotherapy, is extremely poor. In the phase I/II study of pralatrexate in Japanese patients with relapsed or refractory PTCL, the objective response rate was 45%, the median PFS was 150 days, and long-term remission or disease maintenance was possible in approximately 20% of the patients. However, the characteristics of patients who respond to pralatrexate are unknown. Against this background, we investigated common patient characteristics in patients who achieved long-term responses to pralatrexate. Five patients were included and their characteristics were evaluated. The disease types were PTCL-not otherwise specified (NOS) in four cases and angioimmunoblastic T-cell lymphoma (AITL) in one case. The median duration of treatment with pralatrexate was 18 months (range: 7-36 months), of which 3 patients are still being treated. There were no pathological or immunohistochemical findings common to cases that responded to pralatrexate, however, of the four PTCL-NOS patients, two were GATA3 positive. Although there are limitations due to the number of cases, considering that the response rate of pralatrexate for PTCL-NOS in existing studies was 32%, these results may lead to future advances in PTCL treatment.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":"65 2","pages":"101-106"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

RB and CHASER as induction therapy for transplant-eligible mantle cell lymphoma. RB和CHASER作为适合移植的套细胞淋巴瘤的诱导疗法。

IF 1.4

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2025-01-01 DOI: 10.3960/jslrt.25011

Toko Saito, Shigeru Kusumoto, Masamitsu Yanada, Seiichi Kato, Yoshitoyo Kagami, Yuka Kawaguchi, Hirofumi Taji, Shinya Hagiwara, Waki Hosoda, Kazuhito Yamamoto

引用次数: 0